Startseite>>Signaling Pathways>> Others>>Apraclonidine (hydrochloride)

Apraclonidine (hydrochloride) (Synonyms: AL0 2145, ALO 2145)

Katalog-Nr.GC42830

Apraclonidin (Hydrochlorid) (ALO 2145), ein selektiver α2- und schwacher α1-Rezeptor-Agonist, senkt wirksam den Augeninnendruck (IOD) im menschlichen Auge.

Products are for research use only. Not for human use. We do not sell to patients.

Apraclonidine (hydrochloride) Chemische Struktur

Cas No.: 73218-79-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
69,00 $
Auf Lager
5mg
63,00 $
Auf Lager
10mg
105,00 $
Auf Lager
25mg
189,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Apraclonidine is an α2-adrenergic receptor (α2-AR) agonist and structural analog of clonidine . It binds to α2-ARs in calf cortex, rat kidney, and rat spleen with IC50 values of 0.9, 4.3, and 4.2 nM, respectively. Apraclonidine also binds to α2-ARs in rat cerebral cortex, pig submandibular gland and lung tissue, and in dog kidney membrane (Kds = 0.87, 5.28, 1.30, and 5.25 nM, respectively). It inhibits noradrenaline-stimulated contraction in guinea pig ileum and rabbit vas deferens (EC50s = 7.59 and 6.76 nM, respectively). Opthalmic formulations containing apraclonidine have been used to treat elevated intraocular pressure.

Bewertungen

Review for Apraclonidine (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apraclonidine (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.